Cazenove Capital Management’s GSK GSK Stock Holding History

Cazenove Capital Management’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2013 Q2	$207K	Buy	+3,316	New	+$210K	0.17%	75

Other funds holding GSK

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

FMI

Fiduciary Management Inc Milwaukee, Wisconsin $7.03B AUM 11.68% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Cazenove Capital Management's GSK Position: Q2 2013 in Review

Cazenove Capital Management opened a new position in GSK (GSK) in Q2 2013: 3,316 shares worth $207K. The stake represents 0.17% of the portfolio and ranks #75 among its holdings.

639 funds tracked by Wall St. Rank hold GSK as of Q2 2013.

Cazenove Capital Management held 3,316 shares of GSK worth $207K as of Q2 2013.
GSK was a new Cazenove Capital Management position in Q2 2013.
GSK made up 0.17% of Cazenove Capital Management's portfolio in Q2 2013, its #75 holding.
639 funds tracked by Wall St. Rank held GSK as of Q2 2013.

Based on Cazenove Capital Management's 13F filing for Q2 2013, filed 14 Aug 2013.